Literature DB >> 7006847

Release of vasodilator prostaglandin, PGI2, from isolated rat lung during vasoconstriction.

N F Voelkel, J G Gerber, I F McMurtry, A S Nies, J T Reeves.   

Abstract

Prostaglandins are generated by the lungs and released into the circulation. Since inhibitors of prostaglandin synthesis enhance hypoxic pulmonary vasoconstriction, we wondered whether vasodilator prostacyclin was synthesized by the lungs in response to vasoconstriction. To test this hypothesis, we measured vasoconstriction induced by angiotensin II in isolated rat lungs before and after inhibition of prostaglandin synthetase. We found that sodium meclofenamate enhanced and prostacyclin and its precursor arachidonate abolished pulmonary vasoconstriction. In lungs labeled with 14C-arachidonate, effluent radioactivity increased after angiotensin II-induced vasoconstriction. Hypoxic vasoconstriction, but not hypoxia per se, caused an increase in lung effluent radioactivity. Chromatographic analysis of lung effluent showed that 6-keto-prostaglandin F1 alpha was the major arachidonic acid metabolite released during pulmonary vasoconstriction. We concluded that prostacyclin is produced by the lungs in response to vasoconstriction. Hypoxia per se seems not to be the adequate stimulus for enhanced lung prostacyclin formation. Lung prostacyclin may protect the pulmonary circulation against excessive vasoconstriction.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7006847     DOI: 10.1161/01.res.48.2.207

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  16 in total

Review 1.  Pathobiology of pulmonary arterial hypertension and right ventricular failure.

Authors:  Norbert F Voelkel; Jose Gomez-Arroyo; Antonio Abbate; Harm J Bogaard; Mark R Nicolls
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

Review 2.  The pulmonary circulation in acute lung injury: a review of some recent advances.

Authors:  M Leeman
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

3.  Halothane inhibits hypoxic pulmonary vasoconstriction in the presence of cyclooxygenase blockade.

Authors:  D Johnson; I Mayers; T Hurst
Journal:  Can J Anaesth       Date:  1990-04       Impact factor: 5.063

4.  Prostacyclin activates tachykinin release from capsaicin-sensitive afferents in guinea-pig bronchi through a ruthenium red-sensitive pathway.

Authors:  C E Mapp; L M Fabbri; A Boniotti; C A Maggi
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

5.  O2 sensing is preserved in mice lacking the gp91 phox subunit of NADPH oxidase.

Authors:  S L Archer; H L Reeve; E Michelakis; L Puttagunta; R Waite; D P Nelson; M C Dinauer; E K Weir
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

Review 6.  Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin.

Authors:  S Moncada
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739

7.  Effect of edema on segmental vascular resistance in isolated perfused rat lungs.

Authors:  R Hillyard; J Anderson; J U Raj
Journal:  Lung       Date:  1991       Impact factor: 2.584

8.  Augmentation of hypoxic pulmonary vasoconstriction in the isolated perfused rat lung by in vitro antagonists of endothelium-dependent relaxation.

Authors:  V L Brashers; M J Peach; C E Rose
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

9.  Recurrent episodes of gram-negative bacteremia or endotoxemia change reactivity of pre- and post-capillary pulmonary segments to angiotensin or free radicals.

Authors:  O C Kirton; R G Gore; L M Reid; R C Jones
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

10.  Comparison of regional pulmonary perfusion in lobar pneumonia during high frequency and conventional mechanical ventilation in sheep.

Authors:  M J Girotti; K Hong; W C Demajo; T R Todd
Journal:  Can J Anaesth       Date:  1987-05       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.